Welcome to Investor Relations

Abbisko Cayman Limited is a R&D-driven, clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. Since our inception, we have established a robust in-house R&D engine underpinned by our outstanding discovery team and multi-dimensional discovery platform. Leveraging strong discovery capabilities, we have strategically designed and developed a rich pipeline of 14 programs focused on oncology, including five assets at clinical stage.

Abbisko Therapeutics Obtains Approval from U.S. FDA to Conduct Phase I Clinical Study of FGFR4 Inhibitor Irpagratinib (ABSK011)
25 Sep 2023, Shanghai—Abbisko Therapeutics Co., Ltd. (“Abbisko” hereafter) today announced that Irpagratinib (ABSK-011), a highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (“FGFR4”) in patients with advanced hepatocellular carcinoma(HCC)has obtained investigational new drug (IND) approval from the U.S. FDA.
Abbisko Therapeutics Obtained Approval from Europe EMA for Pivotal Global Multi-Center Phase III Clinical Trial of CSF-1R Inhibitor Pimicotinib (ABSK021)
11 September 2023, Shanghai – Abbisko Therapeutics Co., Ltd. (HKEX Stock Code: 2256. HK, referred to as “Abbisko Therapeutics” hereafter) announced that the Europe EMA had approved its CSF-1R inhibitor pimicotinib(ABSK021)for a randomized, double-blind,
Milestone — Abbisko Therapeutics Completes the First Patient Dose in US Phase III TGCT Trial of in CSF-1R Inhibitor – Pimicotinib(ABSK021)
2 August 2023, Shanghai – Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter) today announced first patient dosing of “A Phase 3, Randomized, Double-blind
Abbisko will present clinical results of two First-in-Human Studies at the 2023 European Society for Medical Oncology(ESMO)
31 July 2023, Shanghai – Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter) announced that the clinical results of first-in-human study of FGFR4 inhibitor Irpagratinib(ABSK011)and the clinical results of first-in-human dose-escalating of PD-L1 inhibitor ABSK043 with advanced solid tumors will be presented at the 2023
  • {{item.calendar_date.substr(8,2)}}
    {{item.meeting_time}} {{item.address}} {{item.address}}

Copyright © 2021 All rights reserved:Abbisko Therapeautics     沪ICP备17056565号